Published in J Hypertens on October 01, 2005
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Angiotensin II blockade and aortic-root dilation in Marfan's syndrome. N Engl J Med (2008) 7.31
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
Circulating transforming growth factor-beta in Marfan syndrome. Circulation (2009) 2.69
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A (2011) 2.27
TGFβ receptor mutations impose a strong predisposition for human allergic disease. Sci Transl Med (2013) 2.08
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
TGF-beta signal transduction in chronic kidney disease. Front Biosci (Landmark Ed) (2009) 1.41
Angiotensin II-dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest (2013) 1.32
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart. J Biol Chem (2009) 1.10
Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension. Am J Physiol Renal Physiol (2012) 1.05
Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial. Trials (2010) 1.04
The microfibril hypothesis of glaucoma: implications for treatment of elevated intraocular pressure. J Ocul Pharmacol Ther (2014) 1.03
Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet (2010) 1.03
Fibrillin assemblies: extracellular determinants of tissue formation and fibrosis. Fibrogenesis Tissue Repair (2010) 0.95
Losartan prevents acquired epilepsy via TGF-β signaling suppression. Ann Neurol (2014) 0.92
Approaching a new age in Duchenne muscular dystrophy treatment. Neurotherapeutics (2008) 0.88
Lentiviral-mediated RNA interference against TGF-beta receptor type II in renal epithelial and fibroblast cell populations in vitro demonstrates regulated renal fibrogenesis that is more efficient than a nonlentiviral vector. J Biomed Biotechnol (2010) 0.83
Circulating TGF-beta1 as a reliable biomarker for chronic kidney disease progression in the African-American population. Kidney Int (2009) 0.82
Identification of retinoic acid in a high content screen for agents that overcome the anti-myogenic effect of TGF-beta-1. PLoS One (2010) 0.80
Alternative strategies to manipulate fibrocyte involvement in the fibrotic tissue response: pharmacokinetic inhibition and the feasibility of directed-adipogenic differentiation. Acta Biomater (2014) 0.80
Chronic Kidney Disease and Fibrosis: The Role of Uremic Retention Solutes. Front Med (Lausanne) (2015) 0.78
Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients. Mt Sinai J Med (2010) 0.78
Fibrillin-containing microfibrils are key signal relay stations for cell function. J Cell Commun Signal (2015) 0.78
Anti-TGF-β Antibody, 1D11, Ameliorates Glomerular Fibrosis in Mouse Models after the Onset of Proteinuria. PLoS One (2016) 0.76
Blocking TGF-β Signaling Pathway Preserves Mitochondrial Proteostasis and Reduces Early Activation of PDGFRβ+ Pericytes in Aristolochic Acid Induced Acute Kidney Injury in Wistar Male Rats. PLoS One (2016) 0.76
Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure in mice. Dis Model Mech (2015) 0.76
Elastic band resistance training influences transforming growth factor-ß receptor I mRNA expression in peripheral mononuclear cells of institutionalised older adults: the Vienna Active Ageing Study (VAAS). Immun Ageing (2016) 0.75
miR-181b regulates vascular stiffness age dependently in part by regulating TGF-β signaling. PLoS One (2017) 0.75
Aetiology and management of hereditary aortopathy. Nat Rev Cardiol (2017) 0.75
The role of transforming growth factor β1 in the regulation of blood pressure. Curr Hypertens Rev (2014) 0.75
Kidney dysfunction in patients with pulmonary arterial hypertension. Pulm Circ (2017) 0.75
Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature (2012) 4.26
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2005) 2.13
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. Can J Cardiol (2005) 2.03
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2009) 1.64
The 2001 Canadian recommendations for the management of hypertension: Part two--Therapy. Can J Cardiol (2002) 1.49
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy. Can J Cardiol (2004) 1.46
Endothelin is a dose-dependent trophic factor and a mitogen in small arteries in vivo. Cardiovasc Res (2006) 1.45
Role of oxidative stress in erythropoietin-induced hypertension in uremic rats. Am J Hypertens (2009) 1.44
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood (2005) 1.31
Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int (2004) 1.30
Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol (2003) 1.23
The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2004) 1.20
DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients. Arthritis Rheum (2006) 1.10
Linezolid-associated acute interstitial nephritis and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Am J Kidney Dis (2009) 1.09
Endothelial function and chronic exposure to air pollution in normal male subjects. Hypertension (2007) 1.08
A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum (2004) 1.07
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2010) 1.07
Divergent effects of low versus high dose anti-TGF-beta antibody in puromycin aminonucleoside nephropathy in rats. Kidney Int (2004) 1.06
Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol (2003) 1.05
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol (2008) 1.05
Myofibroblasts enable invasion of endothelial cells into three-dimensional tumor cell clusters: a novel in vitro tumor model. Cancer Chemother Pharmacol (2003) 1.04
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update. Can J Cardiol (2009) 1.03
Local shear stress and brachial artery functions in end-stage renal disease. J Am Soc Nephrol (2007) 1.02
The 2001 Canadian recommendations for the management of hypertension: Part one--Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol (2002) 1.02
Impact of age on glomerular filtration estimates. Nephrol Dial Transplant (2008) 1.01
2010 Canadian Hypertension Education Program (CHEP) recommendations: the scientific summary - an update of the 2010 theme and the science behind new CHEP recommendations. Can J Cardiol (2010) 0.99
Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet. Am J Physiol Heart Circ Physiol (2008) 0.98
Transforming growth factor β neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. PLoS One (2013) 0.95
Determinants of progression of aortic stiffness in hemodialysis patients: a prospective longitudinal study. Hypertension (2013) 0.94
Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol (2006) 0.93
RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol (2011) 0.93
Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest (2005) 0.92
Neutralization of tumor necrosis factor-alpha reduces renal fibrosis and hypertension in rats with renal failure. Am J Nephrol (2012) 0.91
Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. J Hypertens (2002) 0.90
Nonfasting non-high-density lipoprotein cholesterol is adequate for lipid management in hemodialysis patients. Am J Kidney Dis (2005) 0.90
Induction of insulin resistance by high-sucrose feeding does not raise mean arterial blood pressure but impairs haemodynamic responses to insulin in rats. Br J Pharmacol (2002) 0.88
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat. Eur J Pharmacol (2009) 0.87
Vascular remodeling and media calcification increases arterial stiffness in chronic kidney disease. Clin Exp Hypertens (2013) 0.86
Homeostatic role of transforming growth factor-beta in the oral cavity and esophagus of mice and its expression by mast cells in these tissues. Am J Pathol (2009) 0.86
Impact of dialysate calcium concentration on the progression of aortic stiffness in patients on haemodialysis. Nephrol Dial Transplant (2011) 0.84
Estimation of heparin leak into the systemic circulation after central venous catheter heparin lock. Nephrol Dial Transplant (2005) 0.83
Age-related and blood pressure-independent reduction in aortic stiffness after kidney transplantation. J Hypertens (2011) 0.83
A patient with a juxtaglomerular cell tumor with histological vascular invasion. Nat Clin Pract Nephrol (2008) 0.83
Tumor necrosis factor inhibitors as novel therapeutic tools for vascular remodeling diseases. Am J Physiol Heart Circ Physiol (2010) 0.83
eNOS gene delivery prevents hypertension and reduces renal failure and injury in rats with reduced renal mass. Nephrol Dial Transplant (2011) 0.82
Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol (2003) 0.82
Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation. Nephrol Dial Transplant (2007) 0.81
The impact of arteriovenous fistulas on aortic stiffness in patients with chronic kidney disease. Nephrol Dial Transplant (2009) 0.81
Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. Prostaglandins Leukot Essent Fatty Acids (2004) 0.80
Effects of acute variation of dialysate calcium concentrations on arterial stiffness and aortic pressure waveform. Nephrol Dial Transplant (2009) 0.80
Dual-kidney transplants as an alternative for very marginal donors: long-term follow-up in 63 patients. Transplantation (2010) 0.80
Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system. Am J Hypertens (2008) 0.79
Atherosclerotic renovascular disease. Can J Cardiol (2006) 0.79
Effects of high-sucrose feeding on insulin resistance and hemodynamic responses to insulin in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2006) 0.79
Functional tests for primary aldosteronism: value of captopril suppression. Curr Hypertens Rep (2002) 0.78
Arterial stiffness and dialysis calcium concentration. Int J Nephrol (2011) 0.78
Donor-specific antibodies, C4d and their relationship with the prognosis of transplant glomerulopathy. Transplantation (2015) 0.78
Increased ET-1 and reduced ET(B) receptor expression in uremic hypertensive rats. Clin Exp Hypertens (2010) 0.78
Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation (2004) 0.77
Impact of donor age on long-term outcomes after delayed graft function: 10-year follow-up. Transpl Int (2012) 0.77
Active renin mass concentration to determine aldosterone-to-renin ratio in screening for primary aldosteronism. Int J Nephrol Renovasc Dis (2011) 0.77
Morning plasma aldosterone predicts the subtype of primary aldosteronism independent of sodium intake. Clin Exp Hypertens (2007) 0.77
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin. Am J Hypertens (2006) 0.77
Heterogeneity in the acute control of vascular protein synthesis in vivo. J Vasc Res (2003) 0.77
Endothelin-1 levels and cardiovascular risk factors in renal transplant patients. Clin Biochem (2004) 0.77
Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis. Int Urol Nephrol (2013) 0.77
Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats. Can J Physiol Pharmacol (2005) 0.77
Effects of tempol on endothelial and vascular dysfunctions and insulin resistance induced by a high-fat high-sucrose diet in the rat. Can J Physiol Pharmacol (2013) 0.76
Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats. J Cardiovasc Pharmacol (2003) 0.76
The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts. Arthritis Rheum (2012) 0.76
Hypertension in dialysis and kidney transplant patients. Can J Cardiol (2009) 0.75
Green dialysate: asymptomatic perforated cholecystitis without peritonitis. Nephrol Dial Transplant (2006) 0.75
Systolic blood pressure diurnal variation is not a predictor of renal target organ damage in kidney transplant recipients. Am J Transplant (2004) 0.75